Psychiatric Research Institute of Neuroscience in Glasgow (PsyRING), Universities of Glasgow and Strathclyde, Glasgow, UK.
Psychopharmacology (Berl). 2011 Feb;213(4):681-95. doi: 10.1007/s00213-010-2020-7. Epub 2010 Sep 29.
Cognitive deficits are a core feature of schizophrenia that respond minimally to existing drugs. PCP is commonly used to model schizophrenia-like deficits preclinically although different dosing protocols may affect different domains. Here we characterise the acute, and chronic intermittent effects of PCP in the 5-choice serial reaction time task (5-CSRTT) in rats, and assess the effects of clozapine. In a novel approach, we also assess the effects of increased inhibitory load and conduct clinically relevant signal detection analysis (SDA).
The effects of acute and repeated PCP (2.58 mg/kg) treatment on attentional processes and inhibitory control were assessed during and following the chronic treatment regime in the presence or absence of chronic clozapine (20 mg/kg/day).
Thirty minutes post-PCP injection, there was an increase in anticipatory responding which disappeared after 24 h. Although, acute PCP did not change accuracy of responding or processing speed, repeated PCP revealed delayed deficits in cognitive processing speed which were partly ameliorated by clozapine. Extended inter-trial intervals increased premature responding, while SDA revealed that clozapine modified persistent PCP-induced deficits in lnBeta (a composite measure of risk taking versus caution).
Acute NMDA receptor antagonism impairs inhibitory control, whereas repeated treatment produces delayed deficits in cognitive processing speed. The ability of clozapine partially to restore persistent PCP-induced deficits in processing speed and in lnBeta is consistent with clinical findings. This suggests that the enduring effects of repeated PCP treatment, combined with SDA, offers a useful, translational, approach to evaluate novel cognitive enhancers in the 5-CSRTT.
认知缺陷是精神分裂症的核心特征,对现有药物的反应极小。PCP 通常用于临床前模拟精神分裂症样缺陷,尽管不同的给药方案可能会影响不同的领域。在这里,我们描述了 PCP 在大鼠 5 选择序列反应时间任务(5-CSRTT)中的急性和慢性间歇性作用,并评估了氯氮平的作用。在一种新方法中,我们还评估了增加抑制负荷的影响,并进行了临床相关的信号检测分析(SDA)。
在慢性治疗方案期间和之后,评估了急性和重复 PCP(2.58mg/kg)治疗对注意力过程和抑制控制的影响,以及在存在或不存在慢性氯氮平(20mg/kg/天)的情况下。
PCP 注射后 30 分钟,预测反应增加,24 小时后消失。虽然急性 PCP 不改变反应的准确性或处理速度,但重复 PCP 显示认知处理速度延迟缺陷,氯氮平部分改善。延长的试验间间隔增加了过早反应,而 SDA 表明氯氮平改变了持续的 PCP 诱导的 lnBeta(风险与谨慎的综合衡量标准)缺陷。
急性 NMDA 受体拮抗作用损害抑制控制,而重复治疗会导致认知处理速度延迟缺陷。氯氮平部分恢复持续 PCP 诱导的处理速度和 lnBeta 缺陷的能力与临床发现一致。这表明,重复 PCP 治疗与 SDA 相结合,为评估新型认知增强剂在 5-CSRTT 中的应用提供了一种有用的转化方法。